Assessing the impacts of timing on the health benefits, cost-effectiveness and relative affordability of COVID-19 vaccination programmes in 27 African Countries
Liu, Y.; Pearson, C. A.; Madriz Montero, A.; Torres-Rueda, S.; Asfaw, E.; Uzochukwu, B.; Drake, T.; Bergren, E.; Eggo, R. M.; Ruiz, F.; Ndembi, N.; Nonvignon, J.; Jit, M.; Vassall, A.
Show abstract
BackgroundThe COVID-19 vaccine supply shortage in 2021 constrained rollout efforts in Africa while populations experienced waves of epidemics. As supply picks up, a key question becomes if vaccination remains an impactful and cost-effective strategy given changes in the timing of implementation. MethodsWe assessed the impact of timing using an epidemiological and economic model. We fitted our mathematical epidemiological model to reported COVID-19 deaths in 27 African countries to estimate the existing immunity (resulting from infection) before substantial vaccine rollout. We then projected health outcomes for different programme start dates (2021-01-01 to 2021-12-01, n = 12) and roll-out rates (slow, medium, fast; 275, 826, and 2066 doses/ million population-day, respectively) for viral vector and mRNA vaccines. Rollout rates used were derived from observed uptake trajectories. We collected data on vaccine delivery costs by country income group. Lastly, we calculated incremental cost-effectiveness ratios and relative affordability. FindingsVaccination programmes with early start dates incur the most health benefits and are most cost-effective. While incurring the most health benefits, fast vaccine roll-outs are not always the most cost-effective. At a willingness-to-pay threshold of 0.5xGDP per capita, vaccine programmes starting in August 2021 using mRNA and viral vector vaccines were cost-effective in 6-10 and 17-18 of 27 countries, respectively. InterpretationAfrican countries with large proportions of their populations unvaccinated by late 2021 may find vaccination programmes less cost-effective than they could have been earlier in 2021. Lower vaccine purchasing costs and/or the emergence of new variants may improve cost-effectiveness. FundingBill and Melinda Gates Foundation, World Health Organization, National Institute of Health Research (UK), Health Data Research (UK)
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya 96%
- Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study 96%
- Impact of health system strengthening on delivery strategies to improve child immunization coverage and inequalities in rural Madagascar 94%
Similar papers in this journal
- Health impact and cost-effectiveness of COVID-19 vaccination in Sindh Province, Pakistan 97%
- The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries 96%
- Long term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: a modelling study 95%
Similar papers in this journal
- Potential health and economic impact of paediatric vaccination using next generation influenza vaccines in Kenya: a modelling study 97%
- Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis 95%
- Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study 94%
Similar papers in this journal
- COVID-19 vaccine uptake and effectiveness by time since vaccination in the Western Cape province, South Africa: An observational cohort study during 2020-2022 95%
- Epidemiological differences in the impact of COVID-19 vaccination in the United States and China 94%
- The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan 93%
Similar papers in this journal
- Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: a mathematical modelling analysis 95%
- Cost-effectiveness of routine COVID-19 adult vaccination programmes in England 95%
- Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.